KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Debt to Equity (2016 - 2026)

Eli Lilly filings provide 18 years of Debt to Equity readings, the most recent being $1.39 for Q1 2026.

  • On a quarterly basis, Debt to Equity rose 107.88% to $1.39 in Q1 2026 year-over-year; TTM through Mar 2026 was $1.39, a 107.88% increase, with the full-year FY2025 number at $1.6, down 98.83% from a year prior.
  • Debt to Equity hit $1.39 in Q1 2026 for Eli Lilly, down from $1.6 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $393.09 in Q2 2024 to a low of -$720.29 in Q2 2025.
  • Median Debt to Equity over the past 5 years was -$3.92 (2022), compared with a mean of -$31.21.
  • Biggest five-year swings in Debt to Equity: soared 4690.01% in 2022 and later plummeted 12017.71% in 2023.
  • Eli Lilly's Debt to Equity stood at $178.45 in 2022, then plummeted by 104.69% to -$8.37 in 2023, then skyrocketed by 1733.56% to $136.76 in 2024, then tumbled by 98.83% to $1.6 in 2025, then decreased by 13.21% to $1.39 in 2026.
  • The last three reported values for Debt to Equity were $1.39 (Q1 2026), $1.6 (Q4 2025), and $1.78 (Q3 2025) per Business Quant data.